CN102905529A - Compositions comprising non-acidic boswellia oil fraction as bio-enhancer for enhancing the bioavailability of biological agents - Google Patents
Compositions comprising non-acidic boswellia oil fraction as bio-enhancer for enhancing the bioavailability of biological agents Download PDFInfo
- Publication number
- CN102905529A CN102905529A CN2011800262136A CN201180026213A CN102905529A CN 102905529 A CN102905529 A CN 102905529A CN 2011800262136 A CN2011800262136 A CN 2011800262136A CN 201180026213 A CN201180026213 A CN 201180026213A CN 102905529 A CN102905529 A CN 102905529A
- Authority
- CN
- China
- Prior art keywords
- frankincense
- enhancer
- extract
- bio
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to Boswellia derived fraction selected from non-acidic Boswellia low polar gum resin extract fraction (BLPRE), Boswellia volatile oil fraction (BVOIL) or Boswellia oil fraction (BOIL) comprising BLPRE and BVOIL in combination with biological agents for enhancing the bioavailability of said biological agents. The invention also provides composition(s) comprising at least one component selected from Boswellia oil (BOIL), Boswellia volatile oil (BVOIL) and Boswellia low polar gum resin extract (BLPRE) in combination with a biological agent for increasing the bioavailability of biological agent.
Description
Invention field:
The invention provides the low polarity gum resin of nonacid frankincense extracts fraction (BLPRE), frankincense ethereal oil fraction (BVOIL) or contains BLPRE and the frankincense oil fraction of BVOIL (BOIL) is used for improving the bioavilability of biologic product.
The composition of the bioavilability for improving biologic product provided by the invention, it contains a kind of component of being selected from the low polarity gum resin extract (BLPRE) of frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and frankincense and at least in conjunction with a kind of biologic product.
Goal of the invention:
Many medicines, medicinal herb components and bioactive molecule external all be very effective to disease or obstacle.Yet some of them in vivo (warm blooded animal) do not have effect or do not have bioavailability.Therefore, research, identification and invention safety and effectively the preparation bioavilability of helping to improve drug ingedient be very important.In the present invention, the inventor has screened a large amount of extract that comes from plant, animal and microorganism, fraction, plant chemical ingredient and compound.
Background of invention:
Gum olibanum fat has had widely purposes since ancient times.For example, for example the gum resin of boswellia serrata tree plant just is used for the treatment of rheumatoid arthritis and gout by the herbal medicine people of India's medical system industry personage for a long time.The various extracts of gum resin on laboratory animal, all shown potential anti-inflammatory and antiatherosclerosis active [CuaZ-Perolin et al.,
ArteriosclerThrombVascBiolFeb2008].It is found that, Olibanum extract is a kind of potential anti-arthritic [Kimmatkar et al;
Phytomedicine. 2003,10 (1): 3-7].Gum olibanum fat and extract thereof also are proved and can significantly improve curative effect in human clinical test, shown anti-inflammatory effect in the body [E Ernest, BMJ 2008; 337:a2813].
It is owing to one group of triterpenic acid that gum olibanum fat and extract thereof have antiinflammation, and namely masticinic acid is to separate to obtain from the gum resin of boswellia serrata.Masticinic acid demonstrates antiinflammation by suppressing 5-lipoxygenase (5-LOX).The enzyme of a kind of key when 5-LOX is the arachidonic acid synthesis leukotriene.Cyperus iria L. martimi is considered to the generation of inflammation disease and develops relevant.Masticinic acid suppresses the 5-lipoxygenase in addition, thereby suppresses human leukocytes elastoser (HLE), the enzyme in the short inflammation path of a kind of difference Safayahi, H., et. al., J. and Pharmacol. Exp. Ther., 1997:281; P 460-463 ].3-O-acetyl group-11-ketone-beta boswellic acid (AKBA) is the strongest composition of biologic activity in it is similar, and it suppresses the IC of 5-LOX
50Be 1.5 μ M[Sailer, E.R., et. al., British J. Pharmacol., 1996:117; P 615-618].
US Patent No. 5716928 and US5665386 relate to a kind of method that increases the bioavilability of oral dewatering medicament compound, comprise when needing the mammal oral drugs compound of compounds for treating, follow essential oil or the essential oil component of q.s, so that when having essential oil or essential oil component the bioavilability of the bioavilability of compound compound when not having essential oil or essential oil component, wherein essential oil or essential oil component are at 0.01wt or still less to have 10% inhibition during concentration active, the minimizing that changes hydroxylation product by measuring cyclosporine into is analyzed, and utilization contains the 250mug rat liver microsome in the sodium phosphate buffer of 1 milliliter 0.1MPH7.4, the analytical system of 1mu cyclosporine and 1mM NADPH (NADPH).
Required the PCT application WO02/15916 of the priority of German patent DE-A10041217 to disclose the dihydro masticinic acid that is derived from frankincense, the acceptable salt of its medicine and hydrogenation extract.Described disclosed patent suggestion prevents and/or treats unwelcome psychosomatic with these compounds, especially health, body and mind and mental illness, the inflammatory process that causes such as the rising by increase, leukocyte elastase or the plasmin activity of leukotriene formation volume.
According to inventor's understanding, do not relate to nonacid frankincense low polarity gum resin fraction (BLPRE), frankincense ethereal oil fraction (BVOIL) in the prior art or contain BLPRE and the frankincense oil fraction of BVOIL (BOIL) is used for increasing warm blooded animal the bioavilability of biologic product.
Nearly 30% old American does not obtain the dietary requirements that all must nutriment.When using up essential nutriment, the harm of food-drug interaction is well-known.The use that the elderly need to increase medicine is inevitable.For example, use specific antibiotic can reduce the absorption of calcium and iron, and the EDTA chelation therapy can reduce the absorption of zinc, iron, copper and magnesium.
In addition, many foods of the risk increase of cancer and angiocardiopathy that make must be removed from diet, thereby further consume the source of essential nutriment.For example, the good source of Cobastab and vitamin D, restricted often such as red meat, liver, yolk, cheese and dairy produce, because their cholesterol level is high.
Limited menu also causes the consumption of essential amino acid, and such as tryptophan, this is the precursor of very important neurotransmitter, and may be in the effect that prevents brain to bring into play aspect the degeneration at age.Availability that must nutriment further suffers damage because gastrointestinal absorption is poor.
The traditional approach that remedies the metabolism underutilization of nutritional supplementation deficiency, gastrointestinal absorption deficiency and nutriment is the compensation material of n of high dose oral, such as vitamin and mineral supplements.
Therefore, be starved of the compound/composition that exploitation helps to improve the availability of biologic product, improve bioavilability by comprising, improve serum-concentration, improve gastrointestinal absorption, the utilization of improvement system, improve some biological barrier for example the intersection between the skin of respiratory mucosa, mucous membrane of urethra, blood-brain barrier and warm blooded animal be communicated with in one or more interior mechanism.
Summary of the invention:
An importance of the present invention provides the bioavilability that frankincense oil (BOIL) is used for improving biologic product.
Another importance of the present invention provides the bioavilability that frankincense ethereal oil fraction (BVOIL) is used for improving biologic product.
Another importance of the present invention provides the low polarity gum resin of frankincense and extracts the bioavilability that fraction (BLPRE) is used for improving biologic product.
Another aspect of the present invention provides in the warm blooded animal of needs the composition of the bioavilability that improves biologic product, and it contains a kind of component in the low polarity gum resin extract (BLPRE) of the frankincense that is selected from frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and comes from gum olibanum fat at least in conjunction with a kind of biologic product.
Another aspect of the present invention provides the bioavilability that the derivative bio-enhancer of frankincense is used for improving one or more biotic components or functional components.
Another aspect of the present invention provides the bioavilability that the derivative bio-enhancer of frankincense is used for improving one or more medicine goods/synthetic drugs.
Another aspect of the present invention provides the bioavilability that the derivative bio-enhancer of frankincense is used for improving one or more frankincense compositions derived therefroms.
Another aspect of the present invention provides the bioavilability that the derivative bio-enhancer of frankincense is used for improving one or more turmeric compositions derived therefroms.
Description of drawings:
Figure I: the structural formula 1-9 that shows among the figure represents the representative compounds of the low polarity gum resin extract (BSLPRE) of boswellia serrata tree.
Figure II is the serum-concentration diagram of the AKBA that shows, with the dosage that is equivalent to 30mg/kgAKBA to albino rat oral contain the low polarity gum resin extract (BSLPRE) of boswellia serrata tree and selectivity be concentrated into 30%3-O-acetyl group-11-ketone group-masticinic acid (AKBA) boswellia serrata tree extract composition LI13108F and contain boswellia serrata tree ethereal oil fraction (BsVOIL) and after boswellia serrata that selectivity is concentrated into 30%3-O-acetyl group-11-ketone group-masticinic acid (AKBA) sets the composition LI13119F of extract.
Figure III is the serum-concentration diagram of the dinor-curcumin (LI01008) that shows, with concentration 450mg/kg oral contain the composition (LI13124F1) that dinor-curcumin and the low polarity gum resin extract (BSLPRE) of boswellia serrata tree mix with the ratio of 2:1 after or with the concentration of 300mg/kg body weight behind the independent oral dinor-curcumin (LI01008).
Detailed Description Of The Invention:
1, " frankincense oil " used herein or " nonacid Olibanum extract " or " BOIL " representative contains the nonacid gum olibanum fat extract that the low polarity gum resin of the nonacid frankincense that obtains from the gum resin of any Boswellia extracts fraction (BLPRE) and frankincense ethereal oil fraction (BVOIL).
2, " boswellia serrata tree oil " used herein or " nonacid boswellia serrata tree extract " or " BsOIL " representative is set the gum resin extract from the nonacid boswellia serrata that the low polarity gum resin of nonacid boswellia serrata tree extracts fraction (BsLPRE) and boswellia serrata tree ethereal oil fraction (BsVOIL) that contains that the gum resin of boswellia serrata tree obtains.
3, " Ka Shi Boswellia carterii oil " used herein or " nonacid Ka Shi Boswellia carterii extract " or " BcOIL " representative contains the nonacid Ka Shi gum olibanum fat extract that the low polarity gum resin of nonacid Ka Shi Boswellia carterii that obtains from the gum resin of any Ka Shi frankincense seeds extracts fraction (BcLPRE) and Ka Shi Boswellia carterii ethereal oil fraction (BcVOIL).
4, " the low polarity gum resin of frankincense extracts fraction " used herein or the nonacid gum olibanum fat extract oil fraction of " frankincense hangs down polarity gum resin extract " or " BLPRE " representative, it contains removed sesquiterpene, diterpene, triterpenes and other the oiliness phytochemicals that obtains after the volatile component from frankincense oil, and described frankincense oil is to obtain by described any method from the gum resin of any Boswellia.
5, " the low polarity gum resin of boswellia serrata tree oil extracts fraction " used herein or " the low polarity gum resin extract of boswellia serrata tree " or the nonacid boswellia serrata tree of " BsLPRE " representative gum resin extract oil fraction, it contains removed sesquiterpene, diterpene, triterpenes and other the oiliness phytochemicals that obtains after the volatile component from frankincense oil, and described frankincense oil is to obtain by described any method from the gum resin of boswellia serrata tree.
6, " the low polarity gum resin of Ka Shi Boswellia carterii extracts fraction " used herein or the nonacid Ka Shi Boswellia carterii gum resin extract oil fraction of " the Ka Shi Boswellia carterii hangs down polarity gum resin extract " or " BcLPRE " representative, it contains removed sesquiterpene, diterpene, triterpenes and other the oiliness phytochemicals that obtains after the volatile component from Ka Shi Boswellia carterii oil, and described Ka Shi Boswellia carterii oil is to obtain by described any method from the gum resin of Ka Shi frankincense seeds.
7, " frankincense ethereal oil fraction " used herein or " frankincense ethereal oil " or " ethereal oil " or " volatility fraction " or " BVOIL " represent volatility fraction/extract, and it contains monoene, diterpene, ethereal oil and other the oiliness phytochemicals that obtains by the gum resin of any described method from any Boswellia.
8, " boswellia serrata tree ethereal oil fraction " used herein or " boswellia serrata tree ethereal oil " or " tingia ethereal oil " or " tingia volatility fraction or " BsVOIL " represents volatility fraction/extract, and it contains monoene, diterpene, ethereal oil and other oiliness phytochemicals that the gum resin set from boswellia serrata by any described method obtains.
9, " Ka Shi Boswellia carterii ethereal oil fraction " used herein or " Ka Shi Boswellia carterii ethereal oil " or " Ka Shi ethereal oil " or " Ka Shi volatility fraction or " BcVOIL " represent volatility fraction/extract, and it contains monoene, diterpene, ethereal oil and other the oiliness phytochemicals that obtains from the gum resin of any Ka Shi Boswellia carterii by any described method.
10, " natural gum " used herein or " gum resin " or " resin " represent the secretion of frankincense plant species.
11, the pure or half pure compound that from plant, separates of " plant chemical ingredient " used herein representative.
12, " bio-enhancer " refers in warm blooded animal to improve by one or more mechanism the reagent of biologic product availabilities, mechanism wherein comprise improve bioavilability, improve serum-concentration, improve gastrointestinal absorption, the utilization of improvement system, improve some biological barrier for example the intersection between respiratory mucosa, mucous membrane of urethra, blood-brain barrier and the skin be communicated with.
13, " Bioenhanced compositions " refers to contain as the frankincense derived oils fraction of the bio-enhancer composition in conjunction with one or more biologic products.
14, " biologic product " refers to be selected from one or more preparations from bioactive ingredients, functional components, antioxidant, vitamin, mineral matter, amino acid and oil of plant/animal/microorganism/synthetic or semi-synthetic acquisition and composition thereof.
15, " BSE85 % " used herein refers to be standardized as the boswellia serrata extract of 85% masticinic acid.
16, " BCE85% " used herein refers to be standardized as the Ka Shi Olibanum extract of 85% masticinic acid.
17, " CLE95 % " refers to be standardized as the Turmeric P.E of 95% curcumin.
18, " CAE20 % " refers to be standardized as the Radix Curcumae extract of 20% curcumin.
19, " bioactive ingredients " refer to pharmaceutically any or alimentology on or acceptable active component on the diet; Come from plant, animal or microorganism or the compound, extract, fraction, phytochemicals, the synthetic drug that obtain by chemosynthesis or semisynthesis, or their salt or their mixture.
20, " functional components " refers to come from plant or animal or microorganism or chemosynthesis or semisynthetic any medicinal herb components, dietary supplements, antioxidant, vitamin, mineral matter, amino acid, fatty acid, essential oil, fish oil, enzyme, gucosamine, chondroitin and probio or their salt or their mixture.
The gum resin of frankincense has just obtained using very widely since ancient times.The various Boswellias for example gum resin of boswellia serrata tree, Ka Shi Boswellia carterii or frankincense Chinese holly tree are the complex mixtures that contains frankincense oil fraction (BOIL), masticinic acid, carbohydrate and polysaccharide component, and wherein frankincense oil fraction (BOIL) contains essential oil/Olibanum volatile oil fraction (BVOIL) and the low polarity gum resin extraction of nonacid frankincense fraction (BLPRE).Widely used boswellia serrata tree/Ka Shi Boswellia carterii/frankincense Chinese holly tree extract is from the isolated acid fraction of gum resin in the international market, and this fraction is by the standardized 65% or 85% total masticinic acid that contains by analysis by titration.The conventional Olibanum extract (85% total masticinic acid) that comes from boswellia serrata tree/Ka Shi Boswellia carterii/frankincense Chinese holly tree is being carried out in the commercialization process, and the sour fraction that mainly comprises the triterpenic acid that contains masticinic acid is that the remainder from gum resin separates acquisition.In total masticinic acid concentration process, sugar and other polymer are separated and are entered water.The remaining insoluble low polar compound of water is separated and becomes frankincense oil fraction/extract.The compound of these low polarity does not exist or with the low Olibanum extract that is present in the commercial Olibanum extract that is standardized as masticinic acid and optionally concentrates in 3-O-acetyl group-11-ketone group-beta boswellic acid (AKBA) of extremely low concentration in the two.
Obtain the method for nonacid frankincense oil (BOIL) fraction:
A typical method that obtains frankincense oil comprises:
A) obtain the gum resins of one or more plants, described plant be selected from but be not limited to boswellia serrata tree or Ka Shi Boswellia carterii or/frankincense Chinese holly tree or their mixture,
B) utilize water-insoluble organic solvents extraction gum resin,
C) carefully filter extract removing insoluble resin material.
D) utilize aqueous alkali such as potassium hydroxide aqueous solution cyclic washing extractive with organic solvent,
E) utilize water and salt water washing organic layer, and
F) under vacuum and high temperature, evaporate organic layer, to obtain oily residue (BOIL).
Obtain the method for frankincense ethereal oil (BVOIL) fraction:
The method that obtains frankincense ethereal oil (BVOIL) is by steaming or utilize high vacuum from gum olibanum fat.
(BVOIL) typical method that obtains the frankincense ethereal oil comprises:
A) obtain the gum resin of frankincense, and
B) from described gum resin or by steaming or under high vacuum, low temperature the distillation isolate the ethereal oil component, to obtain BVOIL.
In another replaceable method,
A) BOIL prepares by said method,
B) then with BOIL steaming or vacuum distillation to collect frankincense ethereal oil (BVOIL).
Obtain the method for low polarity gum resin extract (BLPRE) fraction of frankincense:
A typical method that obtains the low polarity gum resin extract (BLPRE) of frankincense comprises:
A) utilize the gum resin of water-insoluble organic solvents extraction frankincense Pterostyrax, then carefully filter extract removing insoluble resin material,
B) utilize aqueous alkali such as potassium hydroxide aqueous solution cyclic washing extractive with organic solvent,
C) organic layer that obtains after detergent water and the salt solution alkali cleaning,
D) the described organic layer of evaporation reaches to obtain the oily residue under vacuum and high temperature
E) under high vacuum and high temperature, from described oily residue, remove volatile compound to obtain BLPRE.
Another typical method that obtains the low polarity gum resin extract (BLPRE) of frankincense comprises:
A) alcohols or the hydration alcohols extract of preparation gum olibanum fat,
B) between aqueous alkali and water-insoluble organic solvents, isolate the alcohols extract,
C) Separation of Organic layer, then evaporating solvent reaches to obtain the oily residue
D) under high temperature and high vacuum, from described oily residue, remove volatile compound to obtain BLPRE.
Also have another typical method that obtains the low polarity gum resin extract (BLPRE) of frankincense to comprise:
A) utilize the gum resin of alcohols or hydration alcohols extracting Boswellia,
B) the evaporation organic solvent is to the optimum level of total solid matters, then
C) it be alkaline adjusting pH value, PH9-12 preferably,
D) utilize organic solvent to repeat to extract solution,
E) the evaporation organic solvent reaches to obtain the oily residue under vacuum and high temperature
F) under high vacuum and high temperature from described oily residue the evaporating volatile compound to obtain BLPRE.
A typical method that obtains boswellia serrata tree ethereal oil (BsVOIL) comprises:
A) obtain the gum resin that boswellia serrata is set, and
B) from described gum resin or by steaming or under high vacuum, low temperature the distillation isolate the ethereal oil component, to obtain BsVOIL.
Another typical method that obtains Ka Shi Boswellia carterii ethereal oil (BcVOIL) comprises:
A) obtain the gum resin of Ka Shi Boswellia carterii, and
B) from described gum resin or by steaming or under high vacuum, low temperature the distillation isolate the ethereal oil component, to obtain BcVOIL.
The typical method that obtains frankincense ethereal oil (BVOIL) from boswellia serrata tree, Ka Shi Boswellia carterii as mentioned above.Yet, can come from the frankincense Pterostyrax, to obtain any gum resin to be used for making frankincense ethereal oil (BVOIL) with similar method or process.
Obtain the typical method of the low polarity gum resin extract (BsLPRE) of boswellia serrata tree:
A) obtain the gum resin that boswellia serrata is set,
B) utilize water-insoluble organic solvents extraction, then by filtering to isolate insoluble gummy material and abandon,
C) the aqueous alkali cyclic washing extractive with organic solvent that utilizes dilution to be removing acid compound,
D) in succession water and salt water washing organic layer,
E) under vacuum and 60-70 ° of C, evaporate organic layer to obtain the oily residue, reach
F) under high vacuum and high temperature, from described oily residue, remove volatile component to obtain viscous oil, be the low polarity gum resin extract (BsLPRE) of boswellia serrata tree herein.
Replacedly, BsLPRE also can prepare by the following method:
A) alcohols or the hydration alcohols extract of preparation boswellia serrata tree gum resin,
B) between aqueous alkali and water-insoluble organic solvents, isolate the alcohols extract,
C) then Separation of Organic layer evaporates organic layer to obtain the oily residue under vacuum and 60-70 ° of C, reach
D) under high vacuum and high temperature, from described oily residue, remove volatile component to obtain viscous oil, be the low polarity gum resin extract (BsLPRE) of boswellia serrata tree herein.
Another typical method that obtains the low polarity gum resin extract (BcLPRE) of Ka Shi Boswellia carterii comprises:
A) obtain the gum resin of Ka Shi Boswellia carterii,
B) utilize water-insoluble organic solvents extraction gum resin, then by filtering to isolate insoluble gummy material and abandon,
C) the aqueous alkali cyclic washing extractive with organic solvent that utilizes dilution to be removing acid compound,
D) in succession water and salt water washing organic layer,
E) under vacuum and 60-70 ° of C, evaporate organic layer to obtain the oily residue, reach
F) under high vacuum and high temperature, from described oily residue, remove volatile component to obtain viscous oil, be the low polarity gum resin extract (BcLPRE) of Ka Shi Boswellia carterii herein.
Replacedly, BcLPRE also can prepare by the following method:
A) alcohols or the hydration alcohols extract of preparation Ka Shi Boswellia carterii gum resin,
B) between aqueous alkali and water-insoluble organic solvents, isolate the alcohols extract,
C) Separation of Organic layer, then under vacuum and 60-70 ° of C the evaporation organic layer obtaining the oily residue,
D) under high vacuum and high temperature, from described oily residue, remove volatile component to obtain viscous oil, be the low polarity gum resin extract (BcLPRE) of Ka Shi Boswellia carterii herein.
From boswellia serrata tree and Ka Shi Boswellia carterii, obtain the typical method of the low polarity gum resin extract (BLPRE) of frankincense as mentioned above.Yet, can come from the frankincense Pterostyrax, to obtain any gum resin to be used for making low polarity gum resin extract with similar method or process.
The low polarity gum resin extract (BLPRE) of described former frankincense oil (BOIL) or Olibanum volatile oil (BVOIL) or frankincense has consisted of the main component of gum olibanum fat.Yet it has limited commercial use, and it usually abandons as waste material.The potential use of these fractions is slowly undiscovered.The inventor is surprised to find that removing the fraction that obtains behind the volatile compound from boswellia serrata tree oil is that the low polarity gum resin extract (BsLPRE) of boswellia serrata tree has some useful character.
Among the Indian patent application 2229/CHE/2008 that submitted on September 15th, 2008 before us and the PCT application PCT/IN2009/000505 that submitted on September 14th, 2009, we disclose and have comprised the Synergistic compositions that the concentrated fraction of AKBA and boswellia serrata are set nonacid extract (BNRE).BNRE composition and recognition methods thereof are also open in the lump.
Be bordering on most among the Indian patent application 394/CHE/2010 that submitted on February 15th, 2010 at us, we disclose non-masticinic acid fraction and Synergistic compositions thereof.
In the process of research bio-enhancer, the inventor is unexpected to be found, the low polarity gum resin of nonacid frankincense extracts fraction (BLPRE), frankincense ethereal oil fraction (BVOIL) or contains BLPRE and the frankincense oil fraction of BVOIL (BOIL) can improve the bioavilability of bioactivator.To contain the low polarity gum resin extract (BSLPRE of boswellia serrata tree; LI13115) and selectivity be concentrated into 30%3-O-acetyl group-11-ketone group-beta boswellic acid (AKBA) boswellia serrata tree extract composition LI13108F and contain boswellia serrata tree ethereal oil fraction (BsVOIL) and composition LI13119F that boswellia serrata that selectivity is concentrated into 30%3-O-acetyl group-11-ketone group-beta boswellic acid (AKBA) is set extract gives to albino rat.The animal of control group gives the boswellia serrata tree extract that selectivity is concentrated into 30%AKBA.When 0.5,1,2,4,8 hour after oral before the oral test substances and respectively, collect the blood sample of all animals.Utilize LC-MS to analyze the oral administration biaavailability of the AKBA in the comparison frankincense material by the serum AK BA concentration of measuring each test animal.
Surprisingly, composition LI13108F and composition LI13119F have shown preferably oral administration biaavailability, be respectively AUCs14.08 and 11.23, and the AUC that comprises the component (LI13115) of only having boswellia serrata tree extract of 30%AKBA is 9.825.The bioavilability of LI13108F (with the AUC opinion) is higher by 43.33% than LI13115.The bioavilability of LI13119F is higher by 14.33% than LI13115.Described in the details of research such as embodiment 6 and the figure II.
In order to reach best result for the treatment of, active substance should and arrive its avtive spot with the circulation of valid density perfect aspect during required.Improve bioavilability and reduce medicine frequency and do not lose result for the treatment of for realizing result for the treatment of and being vital for the compliance of patient in the chronic treatment.The present invention realizes this purpose by raising oral administration biaavailability of AKBA in the composition that contains BsLPRE or BsVOIL.
The composition (LI13124F1) that contains BSLPRE and new dinor-curcumin by name (LI01008) by comparative analysis in the albefaction rat and independent LI01008 further confirm the effect of the bioavilability of raising BsLPRE.The dinor-curcumin is a kind of potent curcumin chemical compounds, is much better than the non-oxidizability of other other natural curcumin chemical compounds and the other biological of the curcumin of performance is active usually.Compare with the animal of independent supply LI01008, the bioavilability of composition LI13124F1 is better than LI01008 in serum sample.Compare with the independent serum sample of supplying with the animal of LI01008, the serum sample of supplying with the animal of composition LI13124F1 demonstrates and exceeds 75% bioavilability.Experimental study is described in embodiment 6 and figure III.
The nonacid frankincense of above description of contents hangs down polarity gum resin extract (BLPRE), frankincense ethereal oil fraction (BVOIL) or contains BLPRE and the bioavilability of the frankincense oil fraction of BVOL (BOIL) raising bioactivator.Therefore, these bio-enhancers can be used for improving the dosage of curative effect and reduction bioactivator.
The below will describe various embodiments of the invention:
An importance of the present invention provides the bio-enhancer for the bioavilability that improves biologic product, and the frankincense that is selected from frankincense oil (BOIL), frankincense ethereal oil (BVOIL) originally and comes from the gum olibanum fat of frankincense seeds hangs down polarity gum resin extract (BLPRE).
An importance of the present invention provides the composition for the bioavilability that improves biologic product, and the frankincense that contains frankincense oil (BOIL), the frankincense ethereal oil (BVOIL) of one or more scripts that are selected from and come from the gum olibanum fat of frankincense seeds hangs down the composition of polarity gum resin extract (BLPRE) in conjunction with a biologic product.
Another aspect of the present invention provides the derivative bio-enhancer of frankincense, is used for improving bioavilability and/or biological effectiveness or the dietary supplements relevant with animal also except important to the mankind.
Another aspect of the present invention provides the derivative bio-enhancer of frankincense, is used for improving the bioavilability of one or more biotic components or functional components.
Another aspect of the present invention provides the derivative bio-enhancer of frankincense, is used for improving the bioavilability of one or more frankincense compositions derived therefroms.
Another aspect of the present invention provides the derivative bio-enhancer of frankincense, is used for improving the bioavilability of one or more turmeric compositions derived therefroms.
Another aspect of the present invention provides the method for utilizing the derivative bio-enhancer of frankincense to improve the bioavilability of biologic product.
Another aspect of the present invention provides the bio-enhancer that plays a role by one or more mechanism, mechanism wherein comprise improve bioavilability, improve serum-concentration, improve gastrointestinal absorption, the utilization of improvement system and improve some biological barrier for example the intersection between respiratory mucosa, mucous membrane of urethra, blood-brain barrier and the skin be communicated with.
Another aspect of the present invention provides frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and comes from the bio-enhancer of the low polarity gum resin extract (BLPRE) of frankincense of Boswellia gum resin, and wherein this gum resin can be from acquisition the frankincense kind that is selected from boswellia serrata tree, Ka Shi Boswellia carterii and frankincense Chinese holly tree one or more.
Another aspect of the present invention provides for the composition that improves the activity of biologic product at the warm blooded animal biology of needs.
Another aspect of the present invention provides for the composition that improves the bioavilability of nutrition or diet composition the warm blooded animal of needs, and it contains the low polarity gum resin extract (BLPRE) of frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and frankincense.
Acceptable reagent comprises one or more compositions on nutrition/diet, and this composition is selected from phytochemicals, short intelligence agent, antiobesity agent, antiinflammatory, antilipemic agent, the Antiarthritic agent, antidiabetic, antimicrobial, antifungal agent, antitumor agent, drug for hypertension, anodyne, anti-platelet aggregation agent, antiatherosclerotic, antioxidant, antithrombotic agent, antibacterial agent, anti-antimalarial agent, the anti-osteoporosis agent, probiotics, antifungal agent, immunopotentiator, antivirotic, antihistaminic, muscle relaxant, CI, hypnotic and their salt.
Another aspect of the present invention provides be used to the composition that improves one or more biotic components, and this biotic component is selected from synthetic/semisynthetic bioactive ingredients, functional components, medicinal herb components, dietary supplements, nutriment, antioxidant, vitamin, mineral matter, amino acid and oil and their mixture from plant/animal/microorganism.
Described functional components comprises and is selected from nutriment, dietary supplements, nutrient component, medicinal herb components, phytochemicals, animal protein, gucosamine, chondroitin, phytoprotein, fruit extract, animal extracts, algae extract, probio and their salt.
Described medicinal herb components comprises one or more compositions, and this composition is selected from extract/fraction of being derived from Withania kansuensis, bacopa monnieri, frankincense kind, turmeric kind, centella, Herba Sphaeranthi indici, sugar-apple, the full wing elm of entire leaf, betel, horse gram, Moringa and kamuning/phytochemicals and their salt.
Described antioxidant comprises one or more compositions, is selected from vitamin A, vitamin C, vitamin E, alpha-carotene, anti-beta carotene, β kryptoxanthin, lycopene, xanthophyll/zeaxanthin, the yellow alkali alcohol of pine bark biological species compound, germanium, selenium and zinc.
Described vitamin comprises one or more water soluble vitamins, is selected from Cobastab l, vitamin B2, vitamin PP, vitamin B6, Cobastab l2, folic acid and vitamin C; Lipovitamin is selected from vitamin A, vitamin D, vitamin E and vitamin K.
Described mineral matter comprises one or more mineral matters that is selected from calcium, iron, zinc, vanadium, selenium, chromium, iodine, potassium, manganese, copper and magnesium.
Described amino acid comprises one or more amino acid that is selected from lysine, isoleucine, leucine, threonine, valine, tryptophan, phenyl alanine, methionine, L-selenomethionine and composition thereof.
Described oil comprises one or more oil that are selected from omega-fatty acid, linseed oil, fish oil, krill oil, essential oil and volatile oil.
The biologically active of described frankincense derivative compound/phytochemical can improve by bio-enhancer; comprise that the fractionation extract is standardized as one or more masticinic acids, be selected from α-masticinic acid, beta boswellic acid, 3-O-acetyl group-α masticinic acid, 3-O-acetyl group-β masticinic acid, 3-O-acetyl group-11-ketone group-α-masticinic acid, 11-ketone group-beta boswellic acid and 3-O-acetyl group-11-ketone group-beta boswellic acid.
Another aspect of the present invention provides bio-enhancer, is selected from frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and is used for improving the particularly bioavilability of standardized 3-O-acetyl group-11-ketone group-beta boswellic acid (AKBA) of extract/fraction from the low polarity gum resin extract (BLPRE) of frankincense of frankincense gum resin.
Another aspect of the present invention provides frankincense derivative preparation and composition; be used for improving the bioavilability of the phytochemicals that is derived from the frankincense species; include but not limited to masticinic acid, be selected from α-masticinic acid, beta boswellic acid, 3-acetyl group-α masticinic acid, 3-acetyl group-β masticinic acid, 3-acetyl group-11-ketone group-α-masticinic acid, reach 3-O-acetyl group-11-ketone group-beta boswellic acid or their mixture.
Comprise one or more seeds for the preparation of described oil (BOIL) or ethereal oil (BVOIL) or the frankincense seeds that come from the low polarity gum resin extract (BLPRE) of gum resin, be selected from the boswellia serrata tree (
Boswellia serrata), the Ka Shi Boswellia carterii (
Boswellia carterii), frankincense Chinese holly tree (
Boswellia papyrifera), Amire Boswellia carterii (
Boswellia ameero), Bradley tower Boswellia carterii (
Boswellia bullata), the Da Reli Boswellia carterii (
Boswellia dalzielii), this section Reed Boswellia carterii of Christian Dior (
Boswellia dioscorides), the wheat straw Boswellia carterii (
Boswellia elongata), the Pood of section Boswellia carterii (
Boswellia frereana), draw Boswellia carterii (
Boswellia nana), wild Boswellia carterii (
Boswellia neglecta), the Ou Jiadengsi Boswellia carterii (
Boswellia ogadensis), the Pi Luota Boswellia carterii (
Boswellia pirottae), amber amber Wella Boswellia carterii (
Boswellia popoviana), the Suo Biya Boswellia carterii (
Boswellia rivae), sacred Boswellia carterii (
Boswellia sacra) and the Socotra Boswellia carterii (
Boswellia socotrana).
Another aspect of the present invention provides the bioavilability that the low polarity gum resin extract of frankincense oil or frankincense ethereal oil or frankincense is used for improving the derivative extract/fraction of one or more turmerics/component/phytochemicals, improve by bio-enhancer, comprise the standardized curcumin of fractionation extract, Demethoxycurcumin, Bisdemethoxycurcumin, demethyl curcumin, dinor-curcumin, tetrahydro curcumin, tetrahydrochysene Demethoxycurcumin, tetrahydrochysene Bisdemethoxycurcumin, ar-turmerone or their mixture.
Another aspect of the present invention provides bio-enhancer, is selected from frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and is used for improving the particularly bioavilability of standardized curcumin or Demethoxycurcumin or Bisdemethoxycurcumin or their mixture of extract/fraction from the low polarity gum resin extract (BLPRE) of frankincense of frankincense gum resin.
Another aspect of the present invention provides the derivative bio-enhancer of frankincense and is used for raising derived from the bioavilability of one or more phytochemicalss of turmeric, is selected from curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, demethyl curcumin, dinor-curcumin, tetrahydro curcumin, tetrahydrochysene Demethoxycurcumin, tetrahydrochysene Bisdemethoxycurcumin, ar-turmerone or their mixture.
Can by the derivative component of the curcumin of Bioaugnentation derived from turmeric (
Curcuma longa), root tuber of aromatic turmeric (
Curcuma aromatica), the family root tuber of aromatic turmeric (
Curcuma domestica), curcuma zedoary (
Curcuma aeruginosa), RADIX CURCUMAE from Sichuan of China (
Curcuma albicoma), Ah Bi volt Lou like turmeric (
Curcuma albiflora), Jiang Hehua (
Curcuma alismatifolia), RADIX CURCUMAE (
Curcuma angustifolia), large curcuma zedoary (
Curcuma elata), the rust curcuma zedoary (
Curcuma ferruginea), the chrysanthemum turmeric (
Curcuma flaviflora), the poppyhead curcuma zedoary (
Curcuma yunnanensis) and curcuma zedoary (
Curcuma zedoaria).
Another aspect of the present invention provides the typical method that obtains frankincense oil (BOIL), comprising:
A) obtain the gum resins of one or more plants, described plant be selected from but be not limited to boswellia serrata tree or Ka Shi Boswellia carterii or/frankincense Chinese holly tree or their mixture,
B) utilize water-insoluble organic solvents extraction gum resin,
C) carefully filter extract removing insoluble resin material,
D) utilize aqueous alkali such as potassium hydroxide aqueous solution cyclic washing extractive with organic solvent,
E) utilize water and salt water washing organic layer,
F) under vacuum and high temperature, evaporate organic layer to obtain oily residue (BOIL).
Another aspect of the present invention provides the typical method that obtains frankincense ethereal oil (BVOIL), comprising:
A) obtain the gum resin of frankincense,
B) from described gum resin or by steaming or under high vacuum and temperature the distillation isolate the ethereal oil component, to obtain frankincense ethereal oil fraction (BVOIL).
C) replacedly, the BVOIL fraction is separated from the BOIL fraction by the mode of above-mentioned vacuum distillation under high vacuum and temperature.
Another aspect of the present invention provides the typical method of the low polarity gum resin extract (BVOIL) of preparation frankincense, comprising:
A) utilize the gum resin of water-insoluble organic solvents extraction frankincense seeds, and carefully filter extract removing insoluble resin material,
B) utilize aqueous alkali such as potassium hydroxide aqueous solution cyclic washing extractive with organic solvent,
C) utilize the organic layer that obtains after water and the salt solution washing alkali cleaning,
D) under vacuum and high temperature the described organic layer of evaporation obtaining the oily residue,
E) from described oily residue, remove volatile compound to obtain the low polarity gum resin extract (BLPRE) of frankincense.
The water-insoluble organic solvents that is used for extraction is selected from 1,2-dichloroethane, n-hexane, carrene, chloroform, ethyl acetate, n-butanol, methyl iso-butyl ketone (MIBK) (MIBK) or their appropriate combination without limitation.The aqueous alkali that is used for the washing extractive with organic solvent is selected from group I or II group metal hydroxides, comprises without limitation sodium hydroxide, potassium hydroxide, slaked lime and magnesium hydroxide or their mixture.
On the other hand, a kind of selective method for preparing BLPRE comprises:
A) alcohols or the hydration alcohols extract of preparation gum olibanum fat,
B) between aqueous alkali and water-insoluble organic solvents, isolate the alcohols extract,
C) then Separation of Organic layer distills organic layer, obtains a kind of oiliness residue,
D) then under high vacuum and high temperature, the volatile compound in the described oiliness residue is removed, obtained BLPRE.
On the other hand, also have a kind of selective method for preparing the low polarity gum resin extract (BLPRE) of frankincense, comprising:
A) extract gum olibanum fat with alcohols or hydration alcohols;
B) the distillation organic solvent is to the optimum level of total solid, then
C) the pH value is adjusted to alkalescence, is preferably pH9-12,
D) utilize organic solvent to repeat to extract solution,
E) under vacuum and high temperature, evaporate organic solvent, obtain the oily residue,
F) under high vacuum and high temperature from described oily residue the evaporating volatile compound, obtain BLPRE.
The alcohols that uses in the extraction is selected from methyl alcohol, ethanol and propyl alcohol or their appropriate combination without limitation.
On the other hand, the invention provides the low polarity gum resin extract (BLPRE) of the frankincense that comes from the boswellia serrata tree, wherein said extract comprises one or more Phytochemistry labeled compounds, be selected from without limitation guiol (guiol) (1), nephthenol (nephthenol) (2), serratol (serratol) (3), diterpene X (diterpene X) (4), lupeol (lupeol) (5), olive-12-alkene-3 β-alcohol (olean-12-ene-3 beta-ol) (6), olive-12-alkene-3 α-alcohol (olean-12-ene-3 α-ol) (7), wool steroid-8,24-diene-3 α-alcohol (lanosta-8, (8) and Usu-12-alkene-3 α-alcohol (urs-12-ene-3 α-ol) (9) of 24-diene-3 α-ol).
On the other hand, the invention provides and optionally remove the frankincense that obtains behind acid and the volatile compound and hang down polarity gum resin extract.
The composition of the present invention that contains bio-enhancer and biologic product by oral, in skin, intravenous, subcutaneous, peritonaeum, in the rectally, muscle or any suitable mode give warm blooded animal.
Effective every daily dose of bio-enhancer is the scope in 0.001-1500 mg/kg body weight in warm blooded animal.Effective every daily dose of bio-enhancer is the scope in 0.01-500 mg/kg body weight in warm blooded animal.
Effective every daily dose of bio-enhancer is the scope in 0.1-150 mg/kg body weight in warm blooded animal.
Effective every daily dose of bio-enhancer is the scope in 1.5-15 mg/kg body weight in warm blooded animal.
Embodiment:
Embodiment 1:
The method for preparing frankincense oil (BOIL) comprises:
The method for preparing frankincense oil comprises:
A) obtain the gum resins of one or more plants, described plant is selected from but is not limited to boswellia serrata tree or Ka Shi Boswellia carterii or frankincense Chinese holly tree or their mixture,
B) utilize water-insoluble organic solvents extraction gum resin,
C) carefully filter extract removing insoluble resin material,
D) utilize aqueous alkali such as potassium hydroxide aqueous solution cyclic washing extractive with organic solvent,
E) utilize water and salt water washing organic layer, and
F) under vacuum and high temperature, evaporate organic layer, obtain oily residue (BOIL).
Embodiment 2:
The method for preparing frankincense ethereal oil (BVOIL):
The method for preparing the frankincense ethereal oil comprises:
A) obtain the gum resins of one or more plants, described plant is selected from but is not limited to boswellia serrata tree or Ka Shi Boswellia carterii or frankincense Chinese holly tree or their mixture,
B) from described gum resin or by steaming or under high vacuum, low temperature the distillation isolate the ethereal oil component, obtain frankincense ethereal oil (BVOIL).
Embodiment 3:
The preparation of the low polarity gum resin extract (BsLPRE) of boswellia serrata tree:
Set boswellia serrata in methyl iso-butyl ketone (MIBK) (MIBK) solvent that gum resin (100 g) is scattered in 600 mL and at room temperature stir 60min.Insoluble gummy material passes through isolated by filtration.Utilize 2% potassium hydroxide solution (3*200 mL) repeatedly to extract MIBK solution to remove acid compound.In succession utilize subsequently water (400 mL) and salt solution (200 mL) washing MIBK layer.Then evaporation MIBK layer under 70 ° of C decompressions of 60 – is removed volatile component under 110 ° of C of 75 – and high vacuum from the oily residue, obtain the low polarity gum resin extract of boswellia serrata tree or the BsLPRE(12 g of viscosity oily).
Replacedly, the gum resin (250 g) of collecting from the boswellia serrata tree utilizes methyl alcohol (300 mL*3) extraction and the concentrated methanolic extract of collecting.Be dissolved in residue (50 g) in the ethyl acetate (400 mL) and utilize 1N potassium hydroxide (3 *, 100 mL) extraction.Then water (2*200 mL) and salt solution (200 mL) washing organic layer evaporate to obtain frankincense oil.Under high vacuum and 75-110 ° of C, from described oil, evaporate volatile compound to obtain the BsLPRE of 22 g.
In the standard silica gel chromatographic column, BsLPRE is used the solvent that strengthens from the polarity of hexane to the hexane/ethyl acetate mixture to ethyl acetate.Based on the set of the identical fraction of TLC and with the fraction of set respectively repeatedly the mixture by utilizing hexane/ethyl acetate or hexane/acetone as the silicagel column of washing lotion to obtain pure compound.Thereby some impure fractions further obtain pure compound by the HPLC of anti-phase C18 silicagel column of preparation.By
1The H nuclear magnetic resonnance,
13The structure of each compound of Analysis deterrmination of C nuclear magnetic resonnance, DEPT, HSQC and HMBC and a large amount of spectroscopic data, then data and these data with known compound compare.Nine kinds of main compound that identify shown in figure I are guiol (guiol) (1), nephthenol (nephthenol) (2), serratol (serratol) (3), diterpene X (diterpene X) (4), lupeol (lupeol) (5), olive-12-alkene-3 β-alcohol (olean-12-ene-3 beta-ol) (6), olive-12-alkene-3 α-alcohol (olean-12-ene-3 α-ol) (7), wool steroid-8,24-diene-3 α-alcohol (lanosta-8, (8) and Usu-12-alkene-3 α-alcohol (urs-12-ene-3 α-ol) (9) of 24-diene-3 α-ol).Then, adopt the HPLC method to utilize these pure compounds to come the low polarity gum resin extract (BsLPRE) of standardization boswellia serrata tree.As shown in table 1 to the discriminatory analysis of the new composition of BsLPRE based on HPLC and retention time (Rt) analytical method.
Embodiment 4:
The preparation of the low polarity gum resin extract (BcLPRE) of Ka Shi Boswellia carterii:
Ka Shi Boswellia carterii gum resin (100 g) is scattered in methyl iso-butyl ketone (MIBK) (MIBK) solvent of 600 mL and at room temperature stirs 60min.Insoluble gummy material passes through isolated by filtration.Utilize 2% potassium hydroxide solution (3*200 mL) repeatedly to extract MIBK solution to remove acid compound.In succession utilize subsequently water (400 mL) and salt solution (200 mL) washing MIBK layer.Then evaporation MIBK layer under 70 ° of C decompressions of 60 – is removed volatile component under 85 ° of C of 75 – and vacuum from the oily residue, obtain the low polarity gum resin extract of Ka Shi Boswellia carterii or the BcLPRE(9.5 g of viscosity oily).
Replacedly, the gum resin of collecting from the Ka Shi Boswellia carterii (250 g) utilizes methyl alcohol (300 mL*3) extraction and the concentrated methanolic extract of collecting.Be dissolved in residue (50 g) in the ethyl acetate (400 mL) and utilize 1N potassium hydroxide (3 *, 100 mL) extraction.Then water (2*200 mL) and salt solution (200 mL) washing organic layer evaporate to obtain frankincense oil.Under vacuum and 75-85 ° of C, from described oil, evaporate volatile compound to obtain the BcLPRE of 17.75 g.
Embodiment 5
Come from the bioavilability of the 3-O-acetyl group of different frankincense materials-11-ketone group-beta boswellic acid (AKBA) relatively:
Isolation albefaction rat also selects healthy rat to be used for researching and analysing.Before 7 days of research beginning, place the room of distribution to conform the animal of selecting.Will be for the animal Random assignment of research to different processed group, overnight fasting is also freely drunk water, and records body weight and calculates the dosage of each animal based on body weight.Before the oral specimen and after oral 0.5, when 1.2.4.8 and 12 hours, collect the blood sample of all animals.With the blood sample grumeleuse that gathers 10 minutes, and centrifugal 10 minutes of 4 ℃ of lower 1800g.Serum sample and 100 μ LTCA(20%) and 1.8mLHPLC level methyl alcohol deproteinized, centrifugal 10 minutes of 4 ℃ of lower 1800g are used for supernatant the lcms analysis of total AKBA.With the independent standardized 30%AKBA(LI13115 of boswellia serrata tree extract) (AUC:9.825) compare, contain proportional boswellia serrata tree extract selectivity for 2:1 and be concentrated into 30%3-O-acetyl group-11-ketone group-beta boswellic acid (AKBA) (LI13115) and the composition LI13108F of boswellia serrata tree ethereal oil (BsLPRE); And contain proportional for 2:1 the boswellia serrata tree standardized 30%AKBA of extract and the composition LI13119F of boswellia serrata tree steaming oil (BVOIL) demonstrate better oral administration biaavailability, area under a curve (AUC) is respectively 14.08 and 11.23.The bioavilability of LI13108F (with the AUC opinion) exceeds LI13115 43.33%.The bioavilability of LI13119F exceeds LI13115 14.33%.In different time points different disposal treated animal the serum-concentration of AKBA in the table 2 summary.Serum-concentration and time diagram are as shown in figure II.
Embodiment 6:
The bioavilability of LI01008 and its composition compares:
The LI13124F1 animal began the preadaptation environment 7 days in research.Six animals are divided into two groups randomly, and every group comprises 3 animals.Record body weight and based on the body weight calculating dose.Utilize 450mg to contain the LI01008 of the dinor-curcumin (LI01008) of ratio of 2:1 and composition BsLPRE(LI13115) (LI13124F1) or 300mg/kg as the oral feeding animals of the suspension among the 0.5%CMC.At 0.5,1,2,4,6,8 and 12 time point mobile phone blood sample before and after treatment.The blood sample of mobile phone is processed in refrigerated centrifuge, utilizes HPLC level methyl alcohol to the serum sample deproteinized, fully mixes and the centrifugal upper strata albumen of removing.Supernatant is used for the calculating of LI01008 by HPLC.Data are as shown in table 3.
The data demonstration is compared with taking separately LI01008, and the bioavilability of the LI01008 of composition LI13124F1 exceeds 75%.
Should understand, the change of these ordinary skills in the art can realize above-described embodiment and not deviate from scope of the present invention.Therefore, should be appreciated that described specific embodiment or example are not restrictions of the present invention, but in order to be encompassed in the clear and definite purpose of the present invention and the modification in the scope.
Claims (21)
1. bio-enhancer, be selected from the low polarity gum resin extract (BLPRE) of former frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and frankincense or their mixture of the gum resin that comes from the frankincense kind, be used for improving the bioavilability of biologic product.
2. comprise one or more compositions and in conjunction with a kind of composition of biologic product, composition is selected from the low polarity gum resin extract (BLPRE) of former frankincense oil (BOIL), frankincense ethereal oil (BVOIL) and frankincense or their mixture that comes from the frankincense seeds, is used for improving the bioavilability of described biologic product.
3. preparation as claimed in claim 1 or 2 or composition, wherein said gum olibanum fat comes from a plurality of frankincense seeds, is selected from boswellia serrata tree, Ka Shi Boswellia carterii and frankincense Chinese holly tree.
4. bio-enhancer as claimed in claim 1 or 2 or composition are used for the Bioaugnentation activity that improves biologic product warm blooded animal or the mammal of needs.
5. bio-enhancer as claimed in claim 4 or composition, wherein said biologic product are selected from bioactive ingredients, functional components, medicinal herb components, dietary supplements, nutriment, antioxidant, vitamin, mineral matter, amino acid and oil or their mixture.
6. bio-enhancer as claimed in claim 5 or composition, wherein said bioactive ingredients is selected from acceptable active component on the diet, compound, extract, fraction, phytochemicals, synthetic drug or their salt or its mixture.
7. bio-enhancer as claimed in claim 5 or composition, wherein said functional components comprises one or more compositions, is selected from medicinal herb components, dietary supplements, antioxidant, vitamin, mineral matter, amino acid, fatty acid, essential oil, fish oil, enzyme, aminoglucose, chondroitin and probio or their salt or its mixture.
8. such as claim 6 or 7 described bio-enhancer or compositions, wherein said bioactive ingredients and functional components come from plant, animal, microorganism, by synthetic or semi-synthetic obtaining, are used for improving bioavilability.
9. such as claim 5 or 7 described bio-enhancer or compositions, wherein medicinal herb components comprises the one or more compositions that are selected from extract/fraction/phytochemicals and their salt, comes from Withania kansuensis, bacopa monnieri, frankincense kind, turmeric kind, centella, Herba Sphaeranthi indici, mangosteen, sugar-apple, the full wing elm of entire leaf, betel, horse gram, Moringa and kamuning or their mixture.
10. bio-enhancer as claimed in claim 9 or composition; wherein come from extract/fractions of frankincense seeds/phytochemicals and comprise extract or the fraction of standardized one or more masticinic acids, described masticinic acid is selected from α-masticinic acid, beta boswellic acid, 3-O-acetyl group-α masticinic acid, 3-O-acetyl group-β masticinic acid, 3-O-acetyl group-11-ketone group-α-masticinic acid and 3-O-acetyl group-11-ketone group-beta boswellic acid or their mixture.
11. bio-enhancer as claimed in claim 9 or composition wherein come from extract/fractions of frankincense seeds/phytochemicals and comprise extract or the standardized 3-O-acetyl group of fraction-11-ketone group-beta boswellic acid.
12. bio-enhancer as claimed in claim 9 or composition; the phytochemicals that wherein comes from the frankincense seeds comprises masticinic acid, and described masticinic acid is selected from α-masticinic acid, beta boswellic acid, 3-O-acetyl group-α masticinic acid, 3-O-acetyl group-β masticinic acid, 3-O-acetyl group-11-ketone group-α-masticinic acid and 3-O-acetyl group-11-ketone group-beta boswellic acid or their mixture.
13. bio-enhancer as claimed in claim 9 or composition, wherein coming from extract/fraction of turmeric/component/phytochemicals comprises and extract or the standardized one or more components of fraction is selected from curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, demethyl curcumin, dinor-curcumin, tetrahydro curcumin, tetrahydrochysene Demethoxycurcumin, tetrahydrochysene Bisdemethoxycurcumin and ar-turmerone or their mixture.
14. bio-enhancer as claimed in claim 9 or composition, wherein derivative extract or the especially standardized curcumin of fraction of turmeric.
15. bio-enhancer as claimed in claim 9 or composition, wherein the derivative phytochemicals of turmeric comprises curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, demethyl curcumin, dinor-curcumin, tetrahydro curcumin, tetrahydrochysene Demethoxycurcumin, tetrahydrochysene Bisdemethoxycurcumin and ar-turmerone or their mixture.
16. such as claim 5 and 7 described bio-enhancer or compositions, wherein said antioxidant comprises one or more compositions, is selected from vitamin A, vitamin C, vitamin E, alpha-carotene, anti-beta carotene, β kryptoxanthin, lycopene, xanthophyll/zeaxanthin, the yellow alkali alcohol of pine bark biological species compound, germanium, selenium and zinc.
17. such as claim 5 and 7 described bio-enhancer or compositions, wherein said vitamin comprises one or more water soluble vitamins, is selected from Cobastab l, vitamin B2, vitamin PP, vitamin B6, Cobastab l2, folic acid and vitamin C; Lipovitamin is selected from vitamin A, vitamin D, vitamin E and vitamin K.
18. such as claim 5 and 7 described bio-enhancer or compositions, wherein said mineral matter comprises one or more, is selected from calcium, iron, zinc, vanadium, selenium, chromium, iodine, potassium, manganese, copper and magnesium.
19. such as claim 5 and 7 described bio-enhancer or compositions, wherein said amino acid comprises one or more, is selected from lysine, isoleucine, leucine, threonine, valine, tryptophan, phenyl alanine, methionine, L-selenomethionine or its mixture.
20. such as claim 5 and 7 described bio-enhancer or compositions, wherein said described oil comprises one or more, is selected from omega-fatty acid, linseed oil, fish oil, essential oil and volatile oil.
21. bio-enhancer as claimed in claim 3 or composition, the wherein said frankincense seeds that can be used for preparing described oil or volatile oil or low polarity gum resin extract come from gum resin as claimed in claim 3, are selected from Amire Boswellia carterii, Bradley tower Boswellia carterii, Da Reli Boswellia carterii, this section Reed Boswellia carterii of Christian Dior, wheat straw Boswellia carterii, the Pood of section Boswellia carterii, draw Boswellia carterii, wild Boswellia carterii, Ou Jiadengsi Boswellia carterii, Pi Luota Boswellia carterii, amber amber Wella Boswellia carterii, Suo Biya Boswellia carterii, sacred Boswellia carterii and Socotra Boswellia carterii.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN688/CHE/2010 | 2010-05-30 | ||
IN688CH2010 | 2010-05-30 | ||
PCT/IN2011/000364 WO2011151840A2 (en) | 2010-05-30 | 2011-05-26 | Compositions comprising non-acidic boswellia oil fraction as a bio-enhancer for enhancing the bioavailability of biological agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102905529A true CN102905529A (en) | 2013-01-30 |
CN102905529B CN102905529B (en) | 2014-12-10 |
Family
ID=45067155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180026213.6A Active CN102905529B (en) | 2010-05-30 | 2011-05-26 | Compositions comprising non-acidic boswellia oil fraction as bio-enhancer for enhancing the bioavailability of biological agents |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN102905529B (en) |
CA (1) | CA2801157C (en) |
MY (1) | MY169297A (en) |
SG (1) | SG185733A1 (en) |
WO (1) | WO2011151840A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146265A (en) * | 2014-08-28 | 2014-11-19 | 蒋君军 | Loquat core volatile oil health-care antioxidant and preparation method thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20120043A1 (en) * | 2012-02-08 | 2013-08-09 | Aboca Spa Societa Agricola | FORMULATION FOR IBS. |
WO2018179011A1 (en) * | 2017-03-29 | 2018-10-04 | Olene Life Sciences Private Limited | Composition to enhance bioavailability of natural compounds |
WO2021255464A1 (en) * | 2020-06-17 | 2021-12-23 | Norman Hahn | Nutraceutical composition |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060089409A1 (en) * | 2004-06-18 | 2006-04-27 | Laila Nutraceuticals | Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid |
CN1871251A (en) * | 2003-09-26 | 2006-11-29 | 帕纳克斯医药公司 | Novel triterpene derivatives, preparation thereof and use thereof |
US20080275117A1 (en) * | 2006-09-21 | 2008-11-06 | Dan Li | Compositions and Methods Comprising Boswellia Species |
US20080292736A1 (en) * | 2001-07-20 | 2008-11-27 | Council Of Scientific And Industrial Research | Bioavailability enhancing activity of carum carvi extracts and fractions thereof |
CN101400359A (en) * | 2006-03-17 | 2009-04-01 | 草药科学新加坡私人有限公司 | Extracts and methods comprising curcuma species |
CN102711781A (en) * | 2010-02-15 | 2012-10-03 | 莱拉营养食品有限公司 | A novel boswellia low polar gum resin extract and its synergistic compositions |
CN102811728A (en) * | 2010-03-15 | 2012-12-05 | 莱拉营养食品有限公司 | Boswellia oil, its fractions and compositions for enhancing brain function |
-
2011
- 2011-05-26 CA CA2801157A patent/CA2801157C/en active Active
- 2011-05-26 SG SG2012086336A patent/SG185733A1/en unknown
- 2011-05-26 CN CN201180026213.6A patent/CN102905529B/en active Active
- 2011-05-26 MY MYPI2012700971A patent/MY169297A/en unknown
- 2011-05-26 WO PCT/IN2011/000364 patent/WO2011151840A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080292736A1 (en) * | 2001-07-20 | 2008-11-27 | Council Of Scientific And Industrial Research | Bioavailability enhancing activity of carum carvi extracts and fractions thereof |
CN1871251A (en) * | 2003-09-26 | 2006-11-29 | 帕纳克斯医药公司 | Novel triterpene derivatives, preparation thereof and use thereof |
US20060089409A1 (en) * | 2004-06-18 | 2006-04-27 | Laila Nutraceuticals | Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid |
US20090318551A1 (en) * | 2004-06-18 | 2009-12-24 | Ganga Raju Gokaraju | Uses of analogs of 3-o-acetyl-11-keto-beta-boswellic acid |
CN101400359A (en) * | 2006-03-17 | 2009-04-01 | 草药科学新加坡私人有限公司 | Extracts and methods comprising curcuma species |
US20080275117A1 (en) * | 2006-09-21 | 2008-11-06 | Dan Li | Compositions and Methods Comprising Boswellia Species |
CN102711781A (en) * | 2010-02-15 | 2012-10-03 | 莱拉营养食品有限公司 | A novel boswellia low polar gum resin extract and its synergistic compositions |
CN102811728A (en) * | 2010-03-15 | 2012-12-05 | 莱拉营养食品有限公司 | Boswellia oil, its fractions and compositions for enhancing brain function |
Non-Patent Citations (1)
Title |
---|
BASAR S.: "Phytochemical Investigations on Boswellia Species", 《DISSERTATION FOR THE FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DR. RER. NAT.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146265A (en) * | 2014-08-28 | 2014-11-19 | 蒋君军 | Loquat core volatile oil health-care antioxidant and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2801157A1 (en) | 2011-12-08 |
CA2801157C (en) | 2019-07-16 |
SG185733A1 (en) | 2013-01-30 |
WO2011151840A3 (en) | 2012-01-26 |
CN102905529B (en) | 2014-12-10 |
WO2011151840A2 (en) | 2011-12-08 |
MY169297A (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6059756B2 (en) | Novel boswellia low polar rubber resin extract and its synergistic composition | |
Hamza | Anethum graveolens: Physicochemical properties, medicinal uses, antimicrobial effects, antioxidant effect, anti-inflammatory and analgesic effects: A review | |
Nair et al. | Promising anti-diabetes mellitus activity in rats of β-amyrin palmitate isolated from Hemidesmus indicus roots | |
Hossain | A review on Ficus sycomorus: A potential indigenous medicinal plant in Oman | |
George et al. | Phytochemical research in South Africa | |
US10286023B2 (en) | Compositions comprising non-acidic Boswellia oil fraction as a bio-enhancer for enhancing bioavailability of biological agents | |
CN102905529B (en) | Compositions comprising non-acidic boswellia oil fraction as bio-enhancer for enhancing the bioavailability of biological agents | |
Ramya et al. | GC–MS analysis and antimicrobial activity of various solvent extracts from Simarouba glauca leaves | |
Prommaban et al. | Linoleic acid‐rich guava seed oil: Safety and bioactivity | |
Jikah et al. | Turmeric (Curcuma longa): an insight into its food applications, phytochemistry and pharmacological properties | |
Islamy et al. | Immunostimulant Evaluation Of Neem Leaves Againts Non-Specific Immune Of Tilapia Infected By A. hydrophila | |
Mandey et al. | Effect of orally administrated of cucumber (Cucumis sativus L.) seed juice on the performance and carcass parameters of broiler chickens | |
EP2793917B1 (en) | Extract of rhus copallina extract for use as a medicament | |
Mazumder et al. | Archaeobotanical Elucidation of Moringa oleifera: It’s Biological, Ethnopharmacological and Phytochemical Activities | |
Elnour et al. | Black cumin seed oil, protein, protein concentrates, and hydrolysate | |
Yusnaini | The Identification of Phytocompounds from Limonia acidissima L. Fruit: A Short Report and Updated Review–Focusing on Antihyperuricemic and Antiarthritic Activities | |
Zia-ur-Rehman et al. | Association of water based infusion of Allium sativum and Withania somnifera with serum lipid profile of broiler chicks. | |
Nida | Pharmacological importance of Aloe vera | |
Igwenyi et al. | Azadirachta indica fruit juice clears malaria parasites and replenishes blood levels in Plasmodium berghei-infected mice | |
Bamidele et al. | USES AND HEALTH BENEFITS OF MEDICINAL PLANTS | |
Nasirdjan et al. | Biochemical Composition And Medical Value Of Pharmacy Chamomile | |
Mohsin et al. | X-ray fluorescence technique for studying mineral nutrients of Ocimum basilicum seed cultivated in Iraq | |
Abubakar et al. | Comparative Studies on the Different Phytochemical Contents of Garcinia Kola Fruits and It’s Husk Sold in Nasarawa Market: Different Phytochemical Contents of Garcinia Kola Fruits and It’s Husk Sold in Nasarawa Market | |
Herowati et al. | Antibacterial Activity of Topical Polyherbal Formulation on Pseudomonas aeruginosa | |
Steshenko et al. | Polysaccharides research of Thymus pulegioide L. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |